ArticleScientific reports2016
Photodynamic killing of cancer cells by a Platinum(II) complex with cyclometallating ligand.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Natural Product-Based Upconversion-Downshifting Photosensitizers in Photodynamic Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Influence of Functional Groups on Solution and Solid-State Emission in Planar Pt(II) Complexes: Synthesis, Photophysical, and Theoretical Studies.Journal of fluorescence · 2026Article
- Advances in pH-Sensitive Luminescent Transition Metal Complexes for Theranostic Applications.Chemistry, an Asian journal · 2026Review
- Navigating the Challenges of Metallopharmaceutical Agents: Strategies and Predictive Modeling for Skin Cancer Therapy.Pharmaceutics · 2026Review
- Introduction of a 4-Hexyl-2-thienyl Substituent on Pyridine Rings as a Route for Brightly Luminescent 1,3-Di-(2-pyridyl)benzene Platinum(II) Complexes.Molecules (Basel, Switzerland) · 2025Article
- Synthesis of 5-Fluorouracil (5-FU) coated platinum nanoparticles and apoptotic effects on U87 human glioblastoma cells.Cancer cell international · 2025Article
- Aggregation, Photoluminescence, and Cytotoxicity of Pt(II) and Re(I) Complexes Bearing Multimodal-Coordinating Luminophores.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Structural Features and Photophysical and Antiproliferative Properties of MeInorganic chemistry · 2025Article
- Effect of the Substitution of the Mesityl Group with Other Bulky Substituents on the Luminescence Performance of [Pt(1,3-bis(4-Mesityl-pyridin-2-yl)-4,6-difluoro-benzene)Cl].Molecules (Basel, Switzerland) · 2025Article
- Shining New Light on Biological Systems: Luminescent Transition Metal Complexes for Bioimaging and Biosensing Applications.Chemical reviews · 2024Review
- Photoactive monofunctional platinum(II) anticancer complexes of multidentate phenanthridine-containing ligands: photocytotoxicity and evidence for interaction with DNA.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2023Article
- Synthesis and Biological Activities of Luminescent 5,6-Membered Bis(Metallacyclic) Platinum(II) Complexes.Molecules (Basel, Switzerland) · 2023Article
- Platinum(IV) Complexes with Tridentate,Inorganic chemistry · 2023Article
- Fluorescence and phosphorescence lifetime imaging reveals a significant cell nuclear viscosity and refractive index changes upon DNA damage.Scientific reports · 2023Article
- A Novel Class of Cyclometalated Platinum(II) Complexes for Solution-Processable OLEDs.Molecules (Basel, Switzerland) · 2022Article
- Visible Light-Induced Transition Metal Catalysis.Chemical reviews · 2022Review
- Investigation on Optical and Biological Properties of 2-(4-Dimethylaminophenyl)benzothiazole Based Cycloplatinated Complexes.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment.Pharmaceutics · 2021Review
- Biofabricated platinum nanoparticles: therapeutic evaluation as a potential nanodrug against breast cancer cells and drug-resistant bacteria.RSC advances · 2021Article
- Ligand-controlled and nanoconfinement-boosted luminescence employing Pt(ii) and Pd(ii) complexes: from color-tunable aggregation-enhanced dual emitters towards self-referenced oxygen reporters.Chemical science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Photodynamic therapy that uses photosensitizers which only become toxic upon light-irradiation provides a strong alternative to conventional cancer treatment due to its ability to selectively target tumour material without affecting healthy tissue. Transition metal complexes are highly promising PDT agents due to intense visible light absorption, yet the majority are toxic even without light. This study introduces a small, photostable, charge-neutral platinum-based compound, Pt(II) 2,6-dipyrido-4-methyl-benzenechloride, complex 1, as a photosensitizer, which works under visible light. Activation of the new photosensitizer at low concentrations (0.1-1 μM) by comparatively low dose of 405 nm light (3.6 J cm(-2)) causes significant cell death of cervical, colorectal and bladder cancer cell lines, and, importantly, a cisplatin resistant cell line EJ-R. The photo-index of the complex is 8. We demonstrate that complex 1 induces irreversible DNA single strand breaks following irradiation, and that oxygen is essential for the photoinduced action. Neither light, nor compound alone led to cell death. The key advantages of the new drug include a remarkably fast accumulation time (diffusion-controlled, minutes), and photostability. This study demonstrates a highly promising new agent for photodynamic therapy, and attracts attention to photostable metal complexes as viable alternatives to conventional chemotherapeutics, such as cisplatin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.